Study on Progression of Hospitalized Community Acquired Pneumonia in Patients with Severe Preexisting Conditions and Immunosuppression to Predict Severe Sepsis

What this Trial Is About

Pneumonia is a common lung infection often requiring hospital treatment, but predicting the disease course in hospitalized patients remains challenging. While most recover quickly, some develop severe complications like sepsis and organ failure despite treatment. The PROGRESS consortium is studying clinical, genetic, and molecular markers to predict severe pneumonia progression, aiming to improve decisions about intensive care transfer. The PROGRESS-COMORB study extends this research to patients with more serious preexisting conditions and weakened immune systems. This observational, longitudinal study enrolls patients within 48 hours of hospitalization or within 7 days if admitted directly to intensive care and follows their progress closely for up to six days. Baseline assessments include demographic, medical history, and lifestyle data. Clinical scores like the Pneumonia Severity Index and CURB-65 are recorded. Daily lab tests, clinical observations, and therapy details are collected, alongside biomaterial samples for genetic and molecular analysis. Follow-up visits occur at 28, 180, and 360 days after enrollment. Participants undergo ongoing evaluations including vital status, housing situation, pneumonia recurrence, and quality of life assessments. Researchers track disease severity using measures like the Sequential Organ Failure Assessment and Systemic Inflammatory Response Syndrome status. The primary outcome is the worst disease severity recorded between enrollment and day six. Secondary outcomes include mortality, hospitalization duration, time in intensive care, and ventilator use up to one year after enrollment. The study involves detailed monitoring to better understand pneumonia progression in patients with complex health issues.

Study of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression